Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
NCT ID: NCT00401115
Last Updated: 2010-07-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
50 participants
INTERVENTIONAL
2006-09-30
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema
NCT00656643
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
NCT00712491
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
NCT04187443
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
NCT06847854
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
NCT00766337
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Subconjunctival injection
MS-R001 (rapamycin)
Subconjunctival injection in various dosages
2
Intraocular injection
MS-R001 (rapamycin)
Intraocular injection in various dosages
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MS-R001 (rapamycin)
Subconjunctival injection in various dosages
MS-R001 (rapamycin)
Intraocular injection in various dosages
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Visual acuity of 20/40 to 20/200 in study eye
Exclusion Criteria
* Intraocular surgery of the study eye within 90 days prior to study start
* Capsulotomy of the study eye within 30 days prior to study start
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MacuSight, Inc.
INDUSTRY
Santen Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Santen Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pravin Dugel, M.D.
Role: PRINCIPAL_INVESTIGATOR
Retina Consultants of Arizona
Wayne Solley, M.D.
Role: PRINCIPAL_INVESTIGATOR
Texas Retina Associates
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Retina Consultants of Arizona
Phoenix, Arizona, United States
Texas Retina Associates
Arlington, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DR-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.